XFB-19 / Xfibra - LARVOL DELTA

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers. (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Xfibra, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human

A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers. (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Xfibra, Inc. | Trial completion date: Mar 2023 ➔ Dec 2026 | Trial primary completion date: Jan 2023 ➔ Sep 2026

First-in-human • Trial completion date • Trial primary completion date

A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Xfibra, Inc. | Trial completion date: Dec 2022 ➔ Mar 2023 | Initiation date: May 2022 ➔ Aug 2022 | Trial primary completion date: Sep 2022 ➔ Jan 2023

Trial completion date • Trial initiation date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A First-in-human Study of the Safety, Tolerability, and PK of XFB-19 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Xfibra, Inc.

New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases